



# CALIFORNIA STATE SCIENCE FAIR 2013 PROJECT SUMMARY

Name(s) <b>Masih A. Babagoli</b>	Project Number <b>33760</b>
Project Title <b>Structure-Activity Relationship Exploration of Fatty Acid Amide Hydrolase Inhibitors</b>	
<b>Objectives/Goals</b> The goal was to find a fatty acid amide hydrolase inhibitor that is both effective and restricted from the central nervous system. Such a compound would enable raising endocannabinoid, substances associated with having analgesic and anti-inflammatory effects, levels just in the periphery.	<b>Abstract</b> Brain and liver samples were collected from mice previously administered the compounds in different doses. Each compound at each dose was tested in one trial with triplicates ( $n=3$ ). Samples were placed into vials containing lysis buffer, homogenized, and centrifuged at 2100 rpm for 12 min at 4°C, and the supernatants were collected (S1 fraction). In order to quantify the protein, BCA quantification assays were performed. They were analyzed with a plate spectrophotometer with optical density being an indicator for the protein concentration. An ex vivo assay to determine FAAH activity was performed by incubating each sample containing 50 µg of FAAH for 30 minutes with H3-anandamide. Samples were analyzed with scintillation counter.
<b>Methods/Materials</b> Four compounds (ARN354, ARN715, ARN716, and ARN14038) were tested. Each was a derivative of a single compound but just with a different substituent in the para- position of the proximal phenyl ring. When administered orally at a dose of 1 mg/kg, ARN715 did not exhibit good oral bioavailability, while the other 3 compounds did. Only ARN354, ARN716, and ARN715 showed to be peripheral inhibitors. On the other hand, ARN 14038 was not restricted to the periphery. Lastly, ARN354 and ARN716 gained access to the brain when co-administered with Ko-143 (a selective inhibitor of the ABC-transporter abcg2).	<b>Results</b> My hypothesis was correct. Manipulating the specified position did change the peripheral distribution of the compounds. Results showed that the hydroxyl group is necessary for the peripheral character of these compounds since both ARN 354 and ARN 716, with hydroxyl groups in the specified position, failed to inhibit brain FAAH activity at 1mg/kg. ARN715 was not available when administered orally and intra-peritoneally. This compound contains a carboxyl group which significantly increases its polarity. ARN 14038, with a methoxy group, was not a peripheral inhibitor, showing inhibition of FAAH activity in the brain even at very small doses. Apparently, the loss of peripheral character comes with the
<b>Conclusions/Discussion</b> This project was aimed at finding a fatty acid amide hydrolase inhibitor that is both effective and restricted from the central nervous system.	
<b>Summary Statement</b> This project was done at UCI under the direction of Dr. Guillermo Moreno-Sanz. Most of the experimental design was done by him. He administered the compounds and collected samples. After sample collection, I did the majority of the work in analyzing the samples. I was actively involved in all of	
<b>Help Received</b> This project was done at UCI under the direction of Dr. Guillermo Moreno-Sanz. Most of the experimental design was done by him. He administered the compounds and collected samples. After sample collection, I did the majority of the work in analyzing the samples. I was actively involved in all of	